Showing results (1571-1580 of 10,441) with videos related to
Sort By:
Pageof 1,045
AIDS (London, England)|June 27, 2001
Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapyE Martínez, J L Blanco, J A Arnaiz, et al.AIDS (London, England)|June 26, 2001
HIV surveillance among injecting drug usersD C Des Jarlais, K Dehne, J CasabonaAIDS (London, England)|August 16, 2001
Protective effect of CCR5 delta 32 heterozygosity is restricted by SDF-1 genotype in children with HIV-1 infectionS Sei, A M Boler, G T Nguyen, et al.AIDS (London, England)|August 16, 2001
Clinical assessment of HIV-associated lipodystrophy in an ambulatory populationK A Lichtenstein, D J Ward, A C Moorman, et al.AIDS (London, England)|August 16, 2001
Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugsA L Dunne, F M Mitchell, S K Coberly, et al.AIDS (London, England)|August 16, 2001
A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 x 106 /lS L Koletar, A E Heald, D Finkelstein, et al.AIDS (London, England)|August 16, 2001
Puberty in perinatal HIV-1 infection: a multicentre longitudinal study of 212 childrenM de Martino, P A Tovo, L Galli, et al.AIDS (London, England)|August 16, 2001
Timing of the HIV-1 subtype C epidemic in Ethiopia based on early virus strains and subsequent virus diversificationA Abebe, V V Lukashov, G Pollakis, et al.AIDS (London, England)|August 16, 2001
Decreased recovery of CD4 lymphocytes in older HIV-infected patients beginning highly active antiretroviral therapyM B Goetz, W J Boscardin, D Wiley, et al.AIDS (London, England)|August 16, 2001
Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trialsP M Coplan, A A Nikas, R Y Leavitt, et al.Pageof 1,045